Explore the Agenda

8:00 am Check-In & Coffee

Track One

Track One: Opening Your First Early Access Program

9:00 am Workshop A: Expanded Access Programs 101 – Mastering the Fundamentals for Effective Patient Access

Director, Head, Global Medical Operational Excellence & Strategic Planning, Blueprint Medicines
Associate Director, Early Access Program Operations, Blueprint Medicines
  • Gaining a clear understanding of different types of pre-approval access programs and their purpose
  • Mapping the global EAP landscape and navigating basic regulatory and ethical requirements
  • Learning the key roles and responsibilities across clinical, regulatory, supply, and commercial functions

Track Two

Track Two: Advanced Challenges in Early Access Programs

9:00 am Workshop D: Timing & Risk Management in EAP Strategy

Senior Director, Medical Access, Global Oncology Medical Affairs, Daiichi Sankyo
Manager, Office of Medical Access, Daiichi Sankyo
  • Preparing EAP infrastructure early without certainty of trial readouts or approvals
  • Balancing investment risk vs. readiness: how much to build before the data arrives
  • Understanding the real timelines for opening EAPs across different geographies
  • Creating flexible plans that allow quick go/no-go decisions aligned to pivotal data milestones

11:00 am Morning Break & Networking

11:45 am Workshop B: Strategic Enterprise Decision-Making, Challenges & Execution for Gene Therapy Expanded Access Programs

Head, Global Medical Affairs, Orchard Therapeutics
Vice President, Clinical Operations & Data Management, Orchard Therapeutics
  • Defining the Strategic Role of Expanded Access Across the Asset Lifecycle
  • Structured Decision Framework to Determine Whether and When to Launch EAPs
  • Considerations in Execution of Expanded Access Programs
  • End to End Expanded Access Program execution processes

11:45 am Workshop E: Navigating Complex Ethical, Patient-Centric & Paid-for Challenges in EAPs

President & Executive Director, GARDaccess
  • Balancing fairness and feasibility when demand for access exceeds available supply
  • Exploring ethical and operational challenges in paid-for EAP models, and understanding their implications for patient trust and regulatory compliance
  • Design patient-centric governance approaches that balance transparency, feasibility, and sustainability in complex access scenarios
  • Managing expectations and communication with patients, physicians, and advocacy groups when programs evolve, wind down, or require difficult trade-offs

1:45 pm Lunch Break & Networking

2:45 pm Workshop C: Managing EAPs End-to-End: Practical Tools to Deliver Timely & Compliant Access

Senior Manager, Global Clinical Supply Chain, Takeda Pharmaceutical
Head of North America Medical Governance, Chief Medical Officer Governance & Operations, Strategy, Portfolio, & Hubs, EMD Serono
  • Mastering operational steps from program initiation through supply planning, labelling, and logistics
  • Learning tactics for improving physician and site engagement to accelerating patient treatment
  • Understanding how to anticipate and mitigating common operational and regulatory challenges
  • Exploring strategies for program closure or transition to ensuring seamless patient access

2:45 pm Workshop F: Futureproofing EAPs for Sustainability & Scalability

Executive Director, Expanded & Continued Access, Eli Lilly & Co.
  •  Build frameworks for scaling programs consistently across countries and patient populations while maintaining compliance
  • Integrate EAPs into healthcare systems and leverage digital tools to enhance efficiency and monitoring
  • Examine governance models that balance oversight, quality, and flexibility in evolving regulatory landscapes
  • Learn approaches for optimizing vendor partnerships and internal resources for long-term program resilience

4:45 pm Afternoon Break

5:30 pm Workshop G: Designing Expanded Access That Works With – Not Against – Your Clinical Development & Commercial Readiness

Director, Expanded Access Strategy & Customer Success, myTomorrows
Director, Regulatory & Pharmacovigilance, myTomorrows
  • Enable teams to treat Expanded Access as a deliberate strategic choice—rather than a reactive obligation, while keeping patients, data integrity, and launch success in balance
  • Explain how Expanded Access fits into the full product lifecycle from early-stage development through launch and post-commercialization
  • Anticipate and manage cross-functional tensions, balancing perspectives from clinical, regulatory, medical, commercial, manufacturing, and ethics

7:30 pm End of Workshop Day